StreetInsider.com News Articles

Red Light Holland completes acquisition of Filament Health

Thu, 30 Apr 2026 07:37:13 -0400

Red Light Holland Corp. (CSE: TRIP) completed its acquisition of Filament Health Corp. (OTC: FLHLF) on April 29, 2026, through a statutory plan of arrangement under British Columbia's Business Corporations Act, according to a company statement.

Under the transaction terms, Red Light acquired all 270,728,040 outstanding Filament shares at an exchange ratio of 0.36634769 Red Light shares per Filament share. The company issued 99,180,497 consideration shares and an additional 70,836,683 shares for debt settlements. Former Filament shareholders now hold approximately 30% of Red Light's 595,727,901 total outstanding shares.

The acquisition brings together Red Light's distribution network with Filament's pharmaceutical development capabilities and

Red Light Holland completes acquisition of Filament Health

Thu, 30 Apr 2026 07:37:13 -0400

The acquisition brings together Red Light's distribution network with Filament's pharmaceutical development capabilities and

Magdalena Biosciences begins preclinical study of coca for appetite control

Mon, 16 Mar 2026 09:00:09 -0400

Magdalena Biosciences, a joint venture between Jaguar Health Inc. (NASDAQ: JAGX) and Filament Health Corp. (OTC: FLHLF), has initiated a preclinical study evaluating whole leaf coca extract for appetite suppression, according to a company statement.

The one-month study in mice is being conducted in Alberta, Canada. The coca leaf extract represents Magdalena's drug candidate for post-GLP-1 weight loss management, targeting individuals who have discontinued GLP-1 medications and seek to maintain weight loss.

"Indigenous peoples and healers in the Andean region of Peru have utilized coca for centuries to manage hunger and fatigue," said Steven King, Jaguar's Chief Sustainable Supply and Ethnobotanical Research

Magdalena Biosciences begins preclinical study of coca for appetite control

Mon, 16 Mar 2026 09:00:09 -0400

Red Light Holland to acquire Filament Health in all-share deal

Wed, 11 Mar 2026 07:32:14 -0400

Red Light Holland Corp. (CSE: TRIP) announced it will acquire Filament Health Corp. (OTC: FLHLF) through a statutory plan of arrangement under an agreement dated March 10, 2026.

Under the transaction terms, each Filament share will be exchanged for Red Light shares based on an exchange ratio of approximately 0.0756, assuming a floor price of $0.02 per share. The deal will issue up to 182.4 million Red Light shares, with existing Red Light shareholders expected to retain approximately 70% ownership following completion.

The acquisition combines Red Light's mushroom production capabilities with Filament's pharmaceutical manufacturing infrastructure. Filament operates a GMP-compliant facility in Vancouver

Red Light Holland to acquire Filament Health in all-share deal

Wed, 11 Mar 2026 07:32:14 -0400

Red Light Holland Corp. (CSE: TRIP) announced it will acquire Filament Health Corp. (OTC: FLHLF) through a statutory plan of arrangement under an agreement dated March 10, 2026.

The acquisition combines Red Light's mushroom production capabilities with Filament's pharmaceutical manufacturing infrastructure. Filament operates a GMP-compliant facility in Vancouver

Red Light Holland to acquire Filament Health in all-share deal

Tue, 10 Mar 2026 16:42:16 -0400

Red Light Holland Corp. (CSE: TRIP) announced March 10 it signed a definitive agreement to acquire Filament Health Corp. (OTC: FLHLF) through a statutory plan of arrangement. The transaction will give existing Red Light shareholders approximately 70% ownership of the combined company.

Under the agreement, each Filament share will be exchanged for Red Light shares based on an exchange ratio of approximately 0.0756, assuming a floor price of $0.02 per Red Light share. The deal could result in up to 182.4 million new Red Light shares being issued.

The acquisition combines Red Light's mushroom production capabilities with Filament's pharmaceutical manufacturing infrastructure. Filament

Red Light Holland to acquire Filament Health in all-share deal

Tue, 10 Mar 2026 16:42:16 -0400

The acquisition combines Red Light's mushroom production capabilities with Filament's pharmaceutical manufacturing infrastructure. Filament

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference

Thu, 06 Feb 2025 10:00:00 -0400

Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in late 2025/early 2026

SAN FRANCISCO, CA / ACCESS Newswire / February 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Dr. Karen Brunke, Jaguar's EVP of Corporate and Business Development and Acting CEO of Magdalena Biosciences, Inc. (Magdalena), the joint venture formed by Jaguar and

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference

Thu, 06 Feb 2025 10:00:00 -0400

SAN FRANCISCO, CA / ACCESS Newswire / February 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Dr. Karen Brunke, Jaguar's EVP of Corporate and Business Development and Acting CEO of Magdalena Biosciences, Inc. (Magdalena), the joint venture formed by Jaguar and

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference

Thu, 06 Feb 2025 10:00:00 -0400

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference

Thu, 06 Feb 2025 10:00:00 -0400

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum

Tue, 07 Jan 2025 10:00:00 -0400

Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in 2025

SAN FRANCISCO, CA / ACCESSWIRE / January 7, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Dr. Karen Brunke, Jaguar's EVP of Corporate and Business Development and Acting CEO of Magdalena Biosciences, Inc. (Magdalena), the joint venture formed by Jaguar and Filament Health Corp.

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum

Tue, 07 Jan 2025 10:00:00 -0400

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum

Tue, 07 Jan 2025 10:00:00 -0400

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum

Tue, 07 Jan 2025 10:00:00 -0400

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications

Thu, 19 Dec 2024 09:00:00 -0400

Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indications

The import was conducted in collaboration with the government of Peru

Steven King, Ph.D. of Jaguar to speak about the potential promise of coca-based Botanical Drugs at the February 2025 Wisdom of the Leaf Coca Summit in Peru

Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications

SAN FRANCISCO, CA / ACCESSWIRE / December 19, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar") today announced that

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications

Thu, 19 Dec 2024 09:00:00 -0400

Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indications

The import was conducted in collaboration with the government of Peru

Steven King, Ph.D. of Jaguar to speak about the potential promise of coca-based Botanical Drugs at the February 2025 Wisdom of the Leaf Coca Summit in Peru

Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications

SAN FRANCISCO, CA / ACCESSWIRE / December 19, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar") today announced that

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications

Thu, 19 Dec 2024 09:00:00 -0400

Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indications

The import was conducted in collaboration with the government of Peru

Steven King, Ph.D. of Jaguar to speak about the potential promise of coca-based Botanical Drugs at the February 2025 Wisdom of the Leaf Coca Summit in Peru

Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications

SAN FRANCISCO, CA / ACCESSWIRE / December 19, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar") today announced that

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications

Thu, 19 Dec 2024 09:00:00 -0400

Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indications

The import was conducted in collaboration with the government of Peru

Steven King, Ph.D. of Jaguar to speak about the potential promise of coca-based Botanical Drugs at the February 2025 Wisdom of the Leaf Coca Summit in Peru

Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications

SAN FRANCISCO, CA / ACCESSWIRE / December 19, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar") today announced that

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum

Thu, 10 Oct 2024 10:00:00 -0400

SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX) today announced that Dr. Karen Brunke, Jaguar's EVP of Corporate and Business Development and Acting CEO of Magdalena Biosciences, Inc. (Magdalena), the joint venture recently formed by Jaguar and Filament Health Corp.

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum

Thu, 10 Oct 2024 10:00:00 -0400

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum

Thu, 10 Oct 2024 10:00:00 -0400

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum

Thu, 10 Oct 2024 10:00:00 -0400

Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award

Tue, 20 Aug 2024 10:00:00 -0400

Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, is focused on developing novel prescription psychoactive plant-based medicines for various mental health indications

SAN FRANCISCO, CA / ACCESSWIRE / August 20, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Eduardo Zimmer, Ph.D., a key collaborator with Magdalena Biosciences ("Magdalena"), the joint venture formed by Jaguar and Filament Health Corp. (OTCQB:FLHLF)(CBOE CA:FH)(FSE:7QS) to develop novel, natural prescription psychoactive medicines derived from plants for mental health indications, is the